J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.

J&J has maintained that its now-discontinued talc products are safe and do not cause cancer. It previously set aside $400 million to resolve state claims.

Pharmaceutical giant Johnson & Johnson (JNJ) topped fourth-quarter earnings estimates, reporting nearly $21.4 billion in quarterly revenue. Yahoo Finance Health Reporter Anjalee Khemlani monitors h...

The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall ...

The agreement in principle addresses an investigation brought by more than 40 states into the marketing of its talcum-based baby powder.

New Jersey-based pharmaceutical giant Johnson & Johnson (NYSE:JNJ) hit top-line expectations in today's annual earnings call, but slightly undershot with its adjusted earnings results. The company ...

Johnson & Johnson NYSE: JNJ had a solid quarter in Q4 despite the impacts of the Kenvue spin-off and the deleveraging of COVID-19 sales. However, little has emerged to catalyze the bulls, although ...

Johnson & Johnson CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's ex...

Kari Firestone, Aureus Asset Management executive chairman and co-founder, joins 'Squawk Box' to discuss the latest market trends ahead of earnings season.

Johnson & Johnson (NYSE: JNJ) just reported its financial results for the fourth quarter that slightly topped Street estimates. Its shares are roughly flat in premarket on Tuesday.

Johnson & Johnson JNJ, +0.49% said Tuesday it had net earnings of $4.132 billion, or $1.70 a share, for the fourth quarter, up from $3.227 billion, or $1.22 a share, in the year-earlier period. Adj...

Johnson & Johnson on Tuesday reported fourth-quarter profit above Wall Street expectations, helped by demand for its blockbuster psoriasis treatment Stelara and strength in its medical device unit.

The results come six months after J&J completed its spinoff of consumer health unit Kenvue, the company's biggest shake-up in its nearly 140-year history.

For savvy investors, hunting down undervalued stocks can mean unearthing overlooked stocks with big potential. In any market cycle, undervalued stocks are there, waiting to be scooped up at bargain...

Walgreens Boots Alliance disappointed investors with its recent dividend cut. There are other, more solid companies investors can rely on to pay a dividend.